VEA
MYOV

Virtus ETF Advisers’s Myovant Sciences Ltd. MYOV Stock Holding History

Virtus ETF Advisers’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,251
Closed -$303K – 504
2022
Q4 		$303K Sell
11,251
-11,439
-50% -$301K 0.16% 261
2022
Q3 		$408K Buy
22,690
+334
+1% +$5.33K 0.16% 227
2022
Q2 		$278K Buy
22,356
+11,701
+110% +$129K 0.1% 272
2022
Q1 		$142K Sell
10,655
-634
-6% -$8.5K 0.06% 233
2021
Q4 		$176K Buy
11,289
+1,534
+16% +$29.3K 0.07% 262
2021
Q3 		$219K Sell
9,755
-515
-5% -$11.3K 0.1% 247
2021
Q2 		$234K Sell
10,270
-2,187
-18% -$46K 0.1% 234
2021
Q1 		$256K Buy
12,457
+221
+2% +$5.03K 0.11% 283
2020
Q4 		$338K Sell
12,236
-6,088
-33% -$119K 0.14% 179
2020
Q3 		$257K Sell
18,324
-2,493
-12% -$46.4K 0.13% 257
2020
Q2 		$429K Sell
20,817
-3,078
-13% -$41.9K 0.2% 173
2020
Q1 		$180K Sell
23,895
-3,474
-13% -$39K 0.07% 281
2019
Q4 		$425K Sell
27,369
-1,811
-6% -$18.3K 0.07% 239
2019
Q3 		$152K Sell
29,180
-1,619
-5% -$12K 0.03% 275
2019
Q2 		$279K Buy
+30,799
New +$459K 0.06% 250

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Virtus ETF Advisers's MYOV Position: Q1 2023 in Review

Virtus ETF Advisers sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 11,251 shares — an estimated $303K sold.

Virtus ETF Advisers first reported a position in MYOV in Q2 2019 and held it in 15 quarters. The position peaked at $429K in Q2 2020. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • Virtus ETF Advisers reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,251 Myovant Sciences Ltd. shares in Q1 2023, an estimated $303K.
  • Virtus ETF Advisers first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 15 quarters.
  • Virtus ETF Advisers's Myovant Sciences Ltd. position peaked at $429K in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.